Prokidney reports first quarter 2025 financial results and business highlights

Winston-salem, n.c., may 12, 2025 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today reported financial results and business highlights for the first quarter ended march 31, 2025.

PROK Ratings Summary

PROK Quant Ranking